Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein

Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid and/or arsenic trioxide represents a paradigm in targeted cancer therapy because these drugs cause clinical remission by affecting the stability of the fusion oncoprotein promyelocytic leukemia (PML)/retinoic acid receptor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2010-09, Vol.116 (13), p.2324-2331
Hauptverfasser:	Isakson, Pauline, Bjørås, Magnar, Bøe, Stig Ove, Simonsen, Anne
Format:	Artikel
Sprache:	eng
Schlagworte:	Arsenic Trioxide Arsenicals - pharmacology Autophagy - drug effects Autophagy - physiology Biological and medical sciences Cell Differentiation - drug effects Cell Differentiation - physiology Cell Line, Tumor HeLa Cells Hematologic and hematopoietic diseases Humans Intracellular Signaling Peptides and Proteins - metabolism Leukemia, Promyelocytic, Acute - drug therapy Leukemia, Promyelocytic, Acute - metabolism Leukemia, Promyelocytic, Acute - pathology Medical sciences Nuclear Proteins - antagonists & inhibitors Nuclear Proteins - genetics Nuclear Proteins - metabolism Oncogene Proteins, Fusion - antagonists & inhibitors Oncogene Proteins, Fusion - genetics Oncogene Proteins, Fusion - metabolism Oxides - pharmacology Promyelocytic Leukemia Protein Protein-Serine-Threonine Kinases - metabolism Receptors, Retinoic Acid - antagonists & inhibitors Receptors, Retinoic Acid - genetics Receptors, Retinoic Acid - metabolism Retinoic Acid Receptor alpha RNA, Small Interfering - genetics Solubility TOR Serine-Threonine Kinases Transcription Factors - antagonists & inhibitors Transcription Factors - genetics Transcription Factors - metabolism Tretinoin - pharmacology Tumor Suppressor Proteins - antagonists & inhibitors Tumor Suppressor Proteins - genetics Tumor Suppressor Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!